JPRN-jRCT2080220420未知1 期
A Two Part Study in Japanese Patients With mCRC, Consisting of an Open-Label Phase I Part to Assess the Safety and Tolerability of AZD2171 in Combination With FOLFOX Followed by a Phase II, Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy of AZD2171 in Combination With FOLFOX
适应症
试验速览
- 阶段
- 1 期
- 发起方
- AstraZeneca
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable(—)
- 性别
- All
入选标准
- •Ages Eligible for Study: 18 Years and above
- •Genders Eligible for Study: Both
- •Inclusion Criteria:
- •- Metastatic colorectal cancer
- •- WHO performance status 0-1
- •- Life expectancy is 12 weeks or longer
排除标准
- •- Patient with uncontrolled brain metastases
- •- Patient with inappropriate laboratory tests values
- •- Patient with poorly controlled hypertension
研究者
相似试验
已完成
1 期
A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOXMetastatic Colorectal CancerNCT00494221AstraZeneca172
未知
1 期
A Two-Part Study in Japanese Patients With Advanced or Metastatic NSCLC. Open-Label Phase I to Assess the Safety & Tolerability of AZD2171 in Combination With Pac/Carb, Then a Phase II, Randomised, Double-Blind Study to Assess the Efficacy of AZD2171 Alone and in Combination With AZD2171 and Pac/CarbCarcinoma, Non-Small-Cell LungJPRN-jRCT2080220478AstraZeneca
招募中
不适用
The frequency of uMRD in Japanese patients with CLL after 24 months of treatment with Venetoclax plus/minus Rituximab in the 2L+ in the real-world settingChronic Lymphocytic LeukemiaJPRN-UMIN000050967AbbVie GK89
尚未招募
不适用
Multicenter registry study of Japanese patients with inflammatory bowel disease with COVID-19inflammatory bowel disease COVID-19JPRN-UMIN000040656Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine200
招募中
不适用
Clinical Features in Japanese Patients with Chronic Liver Diseases: A multicenter prospective long observational studyChronic liver diseaseJPRN-UMIN000040277Chiba University1,743
